Octostim (Desmopressin Acetate)

Desmopressin Acetate acts on the vasopressin pathway to control water reabsorption and coagulation factors.

• Central diabetes insipidus: helps normalize urine output and plasma sodium levels.
• Nocturnal enuresis: reduces nighttime bladder episodes in children.
• Mild hemophilia A and von Willebrand disease type 1: raises plasma factor VIII and von Willebrand factor levels to improve clotting.

• Desmopressin acetate is a selective vasopressin V2‑receptor agonist. By binding to V2 receptors on renal collecting‑duct cells it stimulates cyclic AMP production, which promotes insertion of aquaporin‑2 water channels into the apical membrane, enhancing water reabsorption. In endothelial cells it triggers release of stored factor VIII and von Willebrand factor, improving haemostatic function.

Desmopressin may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects

• Headache: mild to moderate intensity.
• Nasal congestion or dryness (if administered intranasally).
• Nausea or abdominal discomfort.
• Hyponatraemia: mild reduction in serum sodium.
• Flushing or feeling of warmth.

Serious or Rare Side Effects

• Severe hyponatraemia leading to seizures or coma.
• Thromboembolic events such as deep‑vein thrombosis.
• Allergic reactions including rash, itching or anaphylaxis.
• Cardiac arrhythmias associated with electrolyte shifts.
• Acute pulmonary oedema in patients with fluid overload.

Desmopressin requires careful monitoring in several clinical situations.

• Fluid restriction: limit intake to 1‑1.5 L/24 h when therapy is initiated.
• Hyponatraemia risk: check serum sodium before and during treatment.
• Cardiovascular disease: use cautiously in patients with heart failure or coronary artery disease.
• Pregnancy and lactation: evaluate benefit‑risk before use.
• Concomitant anticoagulants: monitor clotting parameters closely.
• Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Desmopressin can interact with several medicines that affect water balance or coagulation.

Major Interactions (Avoid)

• NSAIDs (e.g., ibuprofen, naproxen): increase risk of hyponatraemia.
• Carbamazepine and other enzyme inducers: reduce desmopressin plasma levels.
• Anticoagulants (warfarin, DOACs): may potentiate bleeding risk when used for haemostatic indications.

Moderate Interactions (Monitor Closely)

• Diuretics (especially thiazides): amplify water‑retention effects.
• Selective serotonin reuptake inhibitors (SSRIs): modestly raise hyponatraemia risk.
• Hormonal contraceptives: may alter fluid balance, requiring sodium monitoring.